Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06020014 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
A Phase 2 study of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 339
- Enrollment target
- 20
- Study locations
NCT06020014: Completed Phase 2 study of Asthma, sponsored by AstraZeneca.
NCT06020014 is a Phase 2 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 339 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06020014, a Phase 2 study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 339 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.
Primary Outcome
CompEx Asthma is a composite surrogate endpoint for exacerbations that captures: - acute worsening events based on a combination of events based on ePRO data (asthma symptoms and rescue medication use), PEF data, and severe asthma exacerbation events.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AZD4604
Study Locations (20)
North Carolina
- Research Site - Charlotte
- Research Site - New Bern
- Research Site - Salisbury
- Research Site - Winston-Salem
California
- Research Site - Newport Beach
- Research Site - Sacramento
Florida
- Research Site - Lakeland
- Research Site - Miami
Michigan
- Research Site - Ann Arbor
- Research Site - Southfield
Alabama
- Research Site - Birmingham
Arizona
- Research Site - Chandler
Georgia
- Research Site - Atlanta
Indiana
- Research Site - Hammond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 339 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2025-10-28 |
| Phase | Phase 2 |
What the finished NCT06020014 record still lists
NCT06020014 is an interventional study that assigns participants to a tested intervention. The registered 339 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06020014 names 20 study sites across 14 states, led by North Carolina, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06020014 about?
NCT06020014 is a clinical study titled "Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA". This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-sev...
What is the current status of trial NCT06020014?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 339 participants. The study started on 2023-11-16. Estimated completion is 2025-10-28.
What conditions does trial NCT06020014 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06020014?
The interventions under investigation include: Placebo (OTHER), AZD4604 (DRUG).
Who is sponsoring clinical trial NCT06020014?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06020014 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06020014's enrollment target sits among peer trials
339 110th of 374 higher than 263 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT04806958 · 340 participants · NA
The PulsePoint Study
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI